Actuate Therapeutics Inc (ACTU) Research

Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.

Market snapshot

Symbol
ACTU
Price
$2.07
Day change
+0.98%
Market cap
$49.5M
P/E ratio
-2.26x
52-week range
1.58-9.22
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$21.00

Recent news

  • Actuate Therapeutics drug improves survival odds in pancreatic cancer trial

    Twice as many advanced pancreas cancer patients who received an experimental drug developed by Actuate Therapeutics with chemotherapy were alive after one year as those treated with chemo ​alone, according to results of a mid-stage trial.

Peer companies

  • Alector, Inc. (ALEC)
  • Applied Therapeutics, Inc. (APLT)
  • Elicio Therapeutics, Inc. (ELTX)
  • Seres Therapeutics, Inc. (MCRB)
  • Molecular Partners AG (MOLN)
  • Nkarta, Inc. (NKTX)
  • PepGen Inc. (PEPG)
  • Spero Therapeutics, Inc. (SPRO)

Recent insider activity

  • Zabrowski Dan — A-Award (15000 shares) on 2026-05-21
  • THOMSON TODD S — A-Award (15000 shares) on 2026-05-21
  • Sawhney Roger — A-Award (15000 shares) on 2026-05-21
  • RONNEBERG AMY L — A-Award (15000 shares) on 2026-05-21
  • Keyes Jason A — A-Award (15000 shares) on 2026-05-21

Open Actuate Therapeutics Inc (ACTU) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.